{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,6,12]],"date-time":"2026-06-12T06:17:20Z","timestamp":1781245040092,"version":"3.54.1"},"reference-count":36,"publisher":"Springer Science and Business Media LLC","issue":"9","license":[{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T00:00:00Z","timestamp":1753660800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/100019531","name":"Apellis Pharmaceuticals","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100019531","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012112","name":"Swedish Orphan Biovitrum","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012112","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Adv Ther"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1007\/s12325-025-03310-8","type":"journal-article","created":{"date-parts":[[2025,7,28]],"date-time":"2025-07-28T11:01:25Z","timestamp":1753700485000},"page":"4641-4658","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Efficacy and Safety Maintained up to 3 Years in Adults with Paroxysmal Nocturnal Hemoglobinuria Receiving Pegcetacoplan"],"prefix":"10.1007","volume":"42","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4485-6025","authenticated-orcid":false,"given":"Carlos","family":"de Castro","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Richard J.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Morag","family":"Griffin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher J.","family":"Patriquin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brian","family":"Mulherin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Britta","family":"H\u00f6chsmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Veena","family":"Selvaratnam","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond Siu Ming","family":"Wong","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Hillmen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regina","family":"Horneff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Uchendu O.","family":"Uchendu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Surova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johan","family":"Szamosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Regis Peffault","family":"de Latour","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,28]]},"reference":[{"issue":"19","key":"3310_CR1","doi-asserted-by":"publisher","first-page":"1253","DOI":"10.1056\/NEJM199511093331904","volume":"333","author":"P Hillmen","year":"1995","unstructured":"Hillmen P, Lewis SM, Bessler M, Luzzatto L, Dacie JV. Natural history of paroxysmal nocturnal hemoglobinuria. N Engl J Med. 1995;333(19):1253\u20138. https:\/\/doi.org\/10.1056\/NEJM199511093331904.","journal-title":"N Engl J Med"},{"issue":"7","key":"3310_CR2","doi-asserted-by":"publisher","first-page":"1505","DOI":"10.1007\/s00277-020-04052-z","volume":"99","author":"H Schrezenmeier","year":"2020","unstructured":"Schrezenmeier H, R\u00f6th A, Araten DJ, et al. Baseline clinical characteristics and disease burden in patients with paroxysmal nocturnal hemoglobinuria (PNH): updated analysis from the International PNH Registry. Ann Hematol. 2020;99(7):1505\u201314. https:\/\/doi.org\/10.1007\/s00277-020-04052-z.","journal-title":"Ann Hematol"},{"key":"3310_CR3","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101158","volume":"64","author":"A Waheed","year":"2024","unstructured":"Waheed A, Shammo J, Dingli D. Paroxysmal nocturnal hemoglobinuria: review of the patient experience and treatment landscape. Blood Rev. 2024;64:101158. https:\/\/doi.org\/10.1016\/j.blre.2023.101158.","journal-title":"Blood Rev"},{"issue":"4","key":"3310_CR4","doi-asserted-by":"publisher","first-page":"703","DOI":"10.1016\/0092-8674(93)90250-t","volume":"73","author":"J Takeda","year":"1993","unstructured":"Takeda J, Miyata T, Kawagoe K, et al. Deficiency of the GPI anchor caused by a somatic mutation of the PIG-A gene in paroxysmal nocturnal hemoglobinuria. Cell. 1993;73(4):703\u201311. https:\/\/doi.org\/10.1016\/0092-8674(93)90250-t.","journal-title":"Cell"},{"issue":"25","key":"3310_CR5","doi-asserted-by":"publisher","first-page":"4985","DOI":"10.1182\/blood-2012-09-311381","volume":"121","author":"A Hill","year":"2013","unstructured":"Hill A, Kelly RJ, Hillmen P. Thrombosis in paroxysmal nocturnal hemoglobinuria. Blood. 2013;121(25):4985\u201396. https:\/\/doi.org\/10.1182\/blood-2012-09-311381.","journal-title":"Blood"},{"issue":"10","key":"3310_CR6","doi-asserted-by":"publisher","first-page":"1304","DOI":"10.1182\/blood.2019003812","volume":"137","author":"RA Brodsky","year":"2021","unstructured":"Brodsky RA. How I treat paroxysmal nocturnal hemoglobinuria. Blood. 2021;137(10):1304\u20139. https:\/\/doi.org\/10.1182\/blood.2019003812.","journal-title":"Blood"},{"issue":"12","key":"3310_CR7","doi-asserted-by":"publisher","first-page":"1157","DOI":"10.1182\/blood.2023021762","volume":"143","author":"RJ Kelly","year":"2024","unstructured":"Kelly RJ, Holt M, Vidler J, et al. Treatment outcomes of complement protein C5 inhibition in 509 UK patients with paroxysmal nocturnal hemoglobinuria. Blood. 2024;143(12):1157\u201366. https:\/\/doi.org\/10.1182\/blood.2023021762.","journal-title":"Blood"},{"key":"3310_CR8","doi-asserted-by":"publisher","first-page":"204062072413075","DOI":"10.1177\/20406207241307500","volume":"15","author":"JJ Shi","year":"2024","unstructured":"Shi JJ, Ozcan YM, Santos CIA, et al. Current landscape of paroxysmal nocturnal hemoglobinuria in the era of complement inhibitors and regulators. Ther Adv Hematol. 2024;15:20406207241307500. https:\/\/doi.org\/10.1177\/20406207241307500.","journal-title":"Ther Adv Hematol"},{"issue":"2","key":"3310_CR9","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1056\/NEJMra2201664","volume":"387","author":"R Notaro","year":"2022","unstructured":"Notaro R, Luzzatto L. Breakthrough hemolysis in PNH with proximal or terminal complement inhibition. N Engl J Med. 2022;387(2):160\u20136. https:\/\/doi.org\/10.1056\/NEJMra2201664.","journal-title":"N Engl J Med"},{"issue":"suppl 4","key":"3310_CR10","doi-asserted-by":"publisher","first-page":"S33","DOI":"10.1002\/ajh.26882","volume":"98","author":"AG Kulasekararaj","year":"2023","unstructured":"Kulasekararaj AG, Lazana I. Paroxysmal nocturnal hemoglobinuria: where are we going. Am J Hematol. 2023;98(suppl 4):S33-43. https:\/\/doi.org\/10.1002\/ajh.26882.","journal-title":"Am J Hematol"},{"issue":"17","key":"3310_CR11","doi-asserted-by":"publisher","first-page":"4094","DOI":"10.1182\/blood-2008-11-189944","volume":"113","author":"AM Risitano","year":"2009","unstructured":"Risitano AM, Notaro R, Marando L, et al. Complement fraction 3 binding on erythrocytes as additional mechanism of disease in paroxysmal nocturnal hemoglobinuria patients treated by eculizumab. Blood. 2009;113(17):4094\u2013100. https:\/\/doi.org\/10.1182\/blood-2008-11-189944.","journal-title":"Blood"},{"key":"3310_CR12","unstructured":"EMPAVELI (pegcetacoplan). Prescribing Information. Apellis; 2025. https:\/\/pi.apellis.com\/files\/PI_Empaveli.pdf. Accessed July 10, 2025."},{"key":"3310_CR13","unstructured":"ASPAVELI (pegcetacoplan). Summary of Product Characteristics. Swedish Orphan Biovitrum AB; 2025. https:\/\/www.ema.europa.eu\/en\/documents\/product-information\/aspaveli-epar-product-information_en.pdf. Accessed July 10, 2025."},{"issue":"11","key":"3310_CR14","doi-asserted-by":"publisher","first-page":"1028","DOI":"10.1056\/NEJMoa2029073","volume":"384","author":"P Hillmen","year":"2021","unstructured":"Hillmen P, Szer J, Weitz I, et al. Pegcetacoplan versus eculizumab in paroxysmal nocturnal hemoglobinuria. N Engl J Med. 2021;384(11):1028\u201337. https:\/\/doi.org\/10.1056\/NEJMoa2029073.","journal-title":"N Engl J Med"},{"issue":"9","key":"3310_CR15","doi-asserted-by":"publisher","first-page":"e648","DOI":"10.1016\/S2352-3026(22)00210-1","volume":"9","author":"RP de Latour","year":"2022","unstructured":"de Latour RP, Szer J, Weitz IC, et al. Pegcetacoplan versus eculizumab in patients with paroxysmal nocturnal haemoglobinuria (PEGASUS): 48-week follow-up of a randomised, open-label, phase\u00a03, active-comparator, controlled trial. Lancet Haematol. 2022;9(9):e648\u201359. https:\/\/doi.org\/10.1016\/S2352-3026(22)00210-1.","journal-title":"Lancet Haematol"},{"key":"3310_CR16","doi-asserted-by":"publisher","first-page":"2468","DOI":"10.1182\/bloodadvances.2022009129","volume":"7","author":"RSM Wong","year":"2023","unstructured":"Wong RSM, Navarro-Cabrera JR, Comia NS, et al. Pegcetacoplan controls hemolysis in complement inhibitor-naive patients with paroxysmal nocturnal hemoglobinuria. Blood Adv. 2023;7:2468\u201378. https:\/\/doi.org\/10.1182\/bloodadvances.2022009129.","journal-title":"Blood Adv"},{"issue":"5","key":"3310_CR17","doi-asserted-by":"publisher","first-page":"2050","DOI":"10.1007\/s12325-024-02827-8","volume":"41","author":"CJ Patriquin","year":"2024","unstructured":"Patriquin CJ, Bogdanovic A, Griffin M, et al. Safety and efficacy of pegcetacoplan in adult patients with paroxysmal nocturnal hemoglobinuria over 48\u00a0weeks: 307 open-label extension study. Adv Ther. 2024;41(5):2050\u201369. https:\/\/doi.org\/10.1007\/s12325-024-02827-8.","journal-title":"Adv Ther"},{"issue":"2","key":"3310_CR18","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1002\/cncr.10245","volume":"94","author":"D Cella","year":"2002","unstructured":"Cella D, Lai J-S, Chang C-H, Peterman A, Slavin M. Fatigue in cancer patients compared with fatigue in the general United States population. Cancer. 2002;94(2):528\u201338. https:\/\/doi.org\/10.1002\/cncr.10245.","journal-title":"Cancer"},{"issue":"11","key":"3310_CR19","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1016\/j.jval.2018.03.013","volume":"21","author":"I Montan","year":"2018","unstructured":"Montan I, L\u00f6we B, Cella D, Mehnert A, Hinz A. General population norms for the functional assessment of chronic illness therapy (FACIT)-Fatigue scale. Value Health. 2018;21(11):1313\u201321. https:\/\/doi.org\/10.1016\/j.jval.2018.03.013.","journal-title":"Value Health"},{"issue":"9","key":"3310_CR20","doi-asserted-by":"publisher","first-page":"1905","DOI":"10.1007\/s00277-022-04887-8","volume":"101","author":"D Cella","year":"2022","unstructured":"Cella D, Sarda SP, Hsieh R, et al. Changes in hemoglobin and clinical outcomes drive improvements in fatigue, quality of life, and physical function in patients with paroxysmal nocturnal hemoglobinuria: post hoc analyses from the phase\u00a0III PEGASUS study. Ann Hematol. 2022;101(9):1905\u201314. https:\/\/doi.org\/10.1007\/s00277-022-04887-8.","journal-title":"Ann Hematol"},{"issue":"11","key":"3310_CR21","doi-asserted-by":"publisher","first-page":"5115","DOI":"10.1007\/s12325-023-02653-4","volume":"40","author":"V Sharma","year":"2023","unstructured":"Sharma V, Koprivnikar J, Drago K, Savage J, Bachelor A. Injection site reactions with long-term pegcetacoplan use in patients with paroxysmal nocturnal hemoglobinuria: a brief report. Adv Ther. 2023;40(11):5115\u201329. https:\/\/doi.org\/10.1007\/s12325-023-02653-4.","journal-title":"Adv Ther"},{"issue":"7","key":"3310_CR22","doi-asserted-by":"publisher","first-page":"1776","DOI":"10.1182\/bloodadvances.2023011691","volume":"8","author":"M Griffin","year":"2024","unstructured":"Griffin M, Kelly RJ, Panse JP, et al. Management of acute breakthrough hemolysis with intensive pegcetacoplan dosing in patients with PNH. Blood Adv. 2024;8(7):1776\u201386. https:\/\/doi.org\/10.1182\/bloodadvances.2023011691.","journal-title":"Blood Adv"},{"key":"3310_CR23","doi-asserted-by":"crossref","unstructured":"Peffault de Latour R, de Castro C, Mulherin B, et al. Characterization of clinically significant breakthrough hemolysis in patients with paroxysmal nocturnal hemoglobinuria treated with pegcetacoplan. HemaSphere. 2024;8(suppl 1):1433\u20134.","DOI":"10.1182\/bloodadvances.2024012672"},{"issue":"4","key":"3310_CR24","doi-asserted-by":"publisher","DOI":"10.1016\/j.rpth.2024.102416","volume":"8","author":"RJ Kelly","year":"2024","unstructured":"Kelly RJ, Nishimori H, Horneff R, et al. Thrombosis and meningococcal infection rates in pegcetacoplan-treated patients with paroxysmal nocturnal hemoglobinuria in the clinical trial and postmarketing settings. Res Pract Thromb Haemost. 2024;8(4): 102416. https:\/\/doi.org\/10.1016\/j.rpth.2024.102416.","journal-title":"Res Pract Thromb Haemost"},{"key":"3310_CR25","doi-asserted-by":"publisher","unstructured":"Peffault de Latour R, Griffin M, Kelly RJ, et al. Hemolysis events in the phase\u00a03 PEGASUS study of pegcetacoplan in patients with paroxysmal nocturnal hemoglobinuria. Blood Adv. 2024;8(11):2718\u201325. https:\/\/doi.org\/10.1182\/bloodadvances.2024012672.","DOI":"10.1182\/bloodadvances.2024012672"},{"issue":"4","key":"3310_CR26","doi-asserted-by":"publisher","first-page":"567","DOI":"10.3324\/haematol.2009.007229","volume":"95","author":"A Hill","year":"2010","unstructured":"Hill A, Rother RP, Arnold L, et al. Eculizumab prevents intravascular hemolysis in patients with paroxysmal nocturnal hemoglobinuria and unmasks low-level extravascular hemolysis occurring through C3 opsonization. Haematologica. 2010;95(4):567\u201373. https:\/\/doi.org\/10.3324\/haematol.2009.007229.","journal-title":"Haematologica"},{"key":"3310_CR27","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2023.101041","volume":"59","author":"AG Kulasekararaj","year":"2023","unstructured":"Kulasekararaj AG, Kuter DJ, Griffin M, Weitz IC, R\u00f6th A. Biomarkers and laboratory assessments for monitoring the treatment of patients with paroxysmal nocturnal hemoglobinuria: differences between terminal and proximal complement inhibition. Blood Rev. 2023;59:101041. https:\/\/doi.org\/10.1016\/j.blre.2023.101041.","journal-title":"Blood Rev"},{"issue":"5","key":"3310_CR28","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1002\/ajh.27242","volume":"99","author":"M Griffin","year":"2024","unstructured":"Griffin M, Kelly R, Brindel I, et al. Real-world experience of pegcetacoplan in paroxysmal nocturnal hemoglobinuria. Am J Hematol. 2024;99(5):816\u201323. https:\/\/doi.org\/10.1002\/ajh.27242.","journal-title":"Am J Hematol"},{"key":"3310_CR29","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2021.100986","volume":"37","author":"X Jin","year":"2021","unstructured":"Jin X, Ren J, Li R, et al. Global burden of upper respiratory infections in 204 countries and territories, from 1990 to 2019. EClinicalMedicine. 2021;37:100986. https:\/\/doi.org\/10.1016\/j.eclinm.2021.100986.","journal-title":"EClinicalMedicine"},{"issue":"suppl 1","key":"3310_CR30","first-page":"1471","volume":"8","author":"J Panse","year":"2024","unstructured":"Panse J, Kelly R, Nishimori H, et al. Thrombosis and meningococcal infection rates in pegcetacoplan patients with paroxysmal nocturnal hemoglobinuria in the post-marketing setting. HemaSphere. 2024;8(suppl 1):1471\u20132.","journal-title":"HemaSphere"},{"key":"3310_CR31","doi-asserted-by":"publisher","first-page":"1060923","DOI":"10.3389\/fimmu.2022.1060923","volume":"13","author":"B Fattizzo","year":"2022","unstructured":"Fattizzo B, Versino F, Zaninoni A, et al. Case report: transfusion independence and abolition of extravascular hemolysis in a PNH patient treated with pegcetacoplan. Front Immunol. 2022;13:1060923. https:\/\/doi.org\/10.3389\/fimmu.2022.1060923.","journal-title":"Front Immunol"},{"issue":"suppl 1","key":"3310_CR32","first-page":"5008","volume":"8","author":"CG Gonzalez","year":"2024","unstructured":"Gonzalez CG, Segurola LO, Elosegui IE, Oyarzabal AA. Pegcetacoplan C3 inhibitor improve residual anemia in PNH patients under treatment C5 inhibitors. Experience tertiary hospital. HemaSphere. 2024;8(suppl 1):5008\u20139.","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"3310_CR33","first-page":"3593","volume":"8","author":"JC Vallero Llamas","year":"2024","unstructured":"Vallero Llamas JC, Gonz\u00e1lez C, Fern\u00e1ndez A, et al. Real-world experience of pegcetacoplan treatment in patients with paroxysmal nocturnal hemoglobinuria (PNH) with unsatisfactory response to previous therapeutic approaches. HemaSphere. 2024;8(suppl 1):3593\u20134.","journal-title":"HemaSphere"},{"issue":"suppl 1","key":"3310_CR34","doi-asserted-by":"publisher","first-page":"5637","DOI":"10.1182\/blood-2023-189167","volume":"142","author":"J Fishman","year":"2023","unstructured":"Fishman J, Min J, Arnett L, Shenoy A. Improvements in hemoglobin and cognitive function from OPERA: a real-world study of pegcetacoplan treatment in US adults with paroxysmal nocturnal hemoglobinuria. Blood. 2023;142(suppl 1):5637\u20138. https:\/\/doi.org\/10.1182\/blood-2023-189167.","journal-title":"Blood"},{"issue":"suppl 6","key":"3310_CR35","doi-asserted-by":"publisher","first-page":"S20","DOI":"10.1016\/j.jval.2023.03.107","volume":"26","author":"J Fishman","year":"2023","unstructured":"Fishman J, Min J, Arnett L, Shenoy A. Early hemoglobin and quality-of-life trends from OPERA: a real-world study of pegcetacoplan treatment in US adults with paroxysmal nocturnal hemoglobinuria. Value Health. 2023;26(suppl 6):S20.","journal-title":"Value Health"},{"issue":"4","key":"3310_CR36","doi-asserted-by":"publisher","first-page":"516","DOI":"10.1111\/ejh.14139","volume":"112","author":"K Wilson","year":"2024","unstructured":"Wilson K, Rich C, Hakimi Z, et al. Pegcetacoplan in paroxysmal nocturnal haemoglobinuria: its use, its clinical effectiveness, and its influence on health-related quality of life and productivity. Eur J Haematol. 2024;112(4):516\u201329. https:\/\/doi.org\/10.1111\/ejh.14139.","journal-title":"Eur J Haematol"}],"container-title":["Advances in Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03310-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12325-025-03310-8\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12325-025-03310-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,9,8]],"date-time":"2025-09-08T04:24:09Z","timestamp":1757305449000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12325-025-03310-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,28]]},"references-count":36,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2025,9]]}},"alternative-id":["3310"],"URL":"https:\/\/doi.org\/10.1007\/s12325-025-03310-8","relation":{},"ISSN":["0741-238X","1865-8652"],"issn-type":[{"value":"0741-238X","type":"print"},{"value":"1865-8652","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,28]]},"assertion":[{"value":"18 April 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 July 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Carlos de Castro reports consultancy at Apellis; data safety monitoring board at Regeneron; advisory board at Omeros; honoraria from Novartis, Alexion, BioCryst, and Apellis; and research funding from Alexion and Apellis. Richard J. Kelly has received research funding from Novartis and Sobi; and consulting fees, honoraria, and speakers bureau fees from Omeros, Otsuka, Florio, Novartis, Roche, Alexion, Sobi, Jazz, and Astellas Pharmaceuticals. Morag Griffin is on the scientific advisory board for BioCryst; received honoraria for advisory boards from Alexion; and is research investigator for Alexion, Apellis,\u00a0and Regeneron. Christopher J. Patriquin has received consultant fees from Alexion, Apellis, Regeneron, Takeda, BioCryst, Sobi, Amgen, and Novartis. Brian Mulherin and Regis Peffault de Latour have nothing to disclose. Britta H\u00f6chsmann consulted for Alexion, Apellis, and Novartis. Veena Selvaratnam has received consultant fees from Apellis. Raymond Siu Ming Wong has received consulting fees, honoraria, research funding, and speaker\u2019s bureau fees from Alexion and F. Hoffmann-La Roche Ltd.; and research funding and speaker\u2019s bureau fees from Apellis. Peter Hillmen and Uchendu O. Uchendu are employees of Apellis and hold stock options. Regina Horneff, Elena Surova, and Johan Szamosi are employees of Sobi and hold stock options or shares. Yiwei Zhang is an employee of Apellis Pharmaceuticals, Inc. and holds stock or stock options.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of Interest"}},{"value":"All study protocols were designed and monitored in accordance with the ethical principles of Good Clinical Practice and the Declaration of Helsinki. Trials were approved by an institutional review board or independent ethics committee at each center (Table\u00a0); the master ethics committees were Advarra (PEGASUS) and Comite de Etica en Investigacion Biomedica IPS Centro Medico Julian Coronel (PRINCE). All patients provided written informed consent before participation. The trials were funded by Apellis Pharmaceuticals and Sobi (Swedish Orphan Biovitrum AB) who provided the investigative medications. The trials were registered under ClinicalTrials.gov NCT03500549 (PEGASUS), NCT04085601 (PRINCE), and NCT03531255 (307 OLE). The datasets generated and\/or analyzed are available from the corresponding author on reasonable request.\u00a0The FACIT and all related works are owned and copyrighted by, and the intellectual property of, David Cella, PhD. Permission for use of the FACIT-Fatigue questionnaire can be obtained by contacting Dr Cella at information@facit.org.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical Approval"}}]}}